SCHEMBL7187315

SCHEMBL7187315

Brc1ccc(C(Br)c2ccc(Br)cc2)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2A6 P11509 1/20 0.53
HTR2A P28223 1/20 0.42
CYP1A2 P05177 1/20 0.41
ALDH1A1 P00352 4/20 0.40
ALOX15 P16050 2/20 0.40
MAPK1 P28482 2/20 0.40
TDP1 Q9NUW8 1/20 0.37
CYP19A1 P11511 1/20 0.37
CYP2C19 P33261 1/20 0.35
ALOX5 P09917 1/20 0.35
CNR1 P21554 1/20 0.35
SLC6A2 P23975 1/20 0.35
SLC6A4 P31645 1/20 0.35
SLC6A3 Q01959 1/20 0.35
CA1 P00915 1/20 0.35
CA2 P00918 1/20 0.35
TSHR P16473 1/20 0.35
CES2 O00748 1/20 0.35
CES1 P23141 1/20 0.35
PYCR1 P32322 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11576225 0.89 HTR2A (0.58) CYP2A6HTR2AALDH1A1MAPK1TDP1
SCHEMBL7269836 0.80 CYP2A6 (0.53) CYP2A6HTR2ACYP1A2ALDH1A1ALOX15
SCHEMBL3105616 0.78 SLC6A2 (0.37) CYP2A6HTR2ACYP1A2ALDH1A1CYP2C19
SCHEMBL22558308 0.76 CYP2A6 (0.57) CYP2A6HTR2ACYP1A2ALDH1A1ALOX15
SCHEMBL1989430 0.76 CYP2A6 (0.57) CYP2A6HTR2ACYP1A2ALDH1A1ALOX15
SCHEMBL810756 0.75 CYP2A6 (0.47) CYP2A6HTR2ACYP1A2ALDH1A1ALOX15
SCHEMBL15111083 0.75 CYP2A6 (0.47) CYP2A6HTR2ACYP1A2ALDH1A1ALOX15
SCHEMBL12880577 0.73 CES2 (0.48) HTR2AMAPK1TSHRCES2CES1
SCHEMBL16099537 0.73 CYP2A6 (0.44) CYP2A6HTR2ACYP1A2ALDH1A1ALOX15
SCHEMBL10744583 0.73 CYP2A6 (0.44) CYP2A6HTR2ACYP1A2ALDH1A1ALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1268494-A1 SULFUR SUBSTITUTED ARYLDIFLUOROMETHYLPHOSPHONIC ACIDS AS PTP-1B INHIBITORS Merck Frosst Canada & Co. (CA) 2003-01-02 EP disclosed
US-6498151-B2 PROTEIN TYROSINE PHOSPHATASES INHIBITORS, ESPECIALLY AS ANTIDIABETIC AGENTS MERCK FROSST CANADA & CO. (CA) 2002-12-24 US disclosed
US-20020091104-A1 Aryldifluoromethylphosphonic acids with sulfur-containing substituents as PTP-1B inhibitors MERCK FROSST CANADA LTD. (CA) 2002-07-11 US disclosed
WO-2001070753-A1 SULFUR SUBSTITUTED ARYLDIFLUOROMETHYLPHOSPHONIC ACIDS AS PTP-1B INHIBITORS MERCK FROSST CANADA & CO. (CA) 2001-09-27 WO disclosed
EP-0361204-B1 Optical recording materials, method for preparing the same and optical cards having the same ASAHI CHEMICAL IND (JP) 1994-11-30 EP disclosed
US-4327176-A IMPACT RESISTANT ACRYLIC ESTER RESIN BINDER ASAHI KASEI KOGYO KABUSHIKI KAISHA (JP) 1982-04-27 US disclosed
US-4268626-A Dry image forming material ASAHI KASEI KOGYO KABUSHIKI KAISHA (JP) 1981-05-19 US disclosed
US-4188226-A OXIDIZER, REDUCER, HALOGENATED CARBOCYCLIC COMPOUND ASAHI KASEI KOGYO KABUSHIKI KAISHA (JP) 1980-02-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020091104-A1 Aryldifluoromethylphosphonic acids with sulfur-containing substituents as PTP-1B inhibitors PTPRF, PTPRS, PTPRO CYP2A6 408/4885HTR2A 3553/4885CYP1A2 2543/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.